MTOR and metastatic neoplasm: The addition of an already FDA approved and well-tolerated mTOR inhibitor, such as rapamycin, to standard-of-care CRT may also provide a treatment option for patients with recurrent/metastatic disease, for which effective treatment options are currently lacking.